Chutima Jansakun

Dr. Chutima Jansakun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
NSNassareen Supaweera
Nassareen Supaweera
WCWanatsanan Chulrik
Wanatsanan Chulrik
CJChutima Jansakun
Chutima Jansakun
PBPhuangthip Bhoopong
Phuangthip Bhoopong
GYGorawit Yusakul
Gorawit Yusakul
WCWarangkana Chunglok
Warangkana Chunglok
A novel HDES-based microemulsion system with anti-inflammatory activity serves as an extraction solvent ofCurcuma longaL.

1 May 2023 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
DGDeniz Göcebe
Deniz Göcebe
CJChutima Jansakun
Chutima Jansakun
YZYuling Zhang
Yuling Zhang
SSSimone Staffer
Simone Staffer
STSabine Tuma-Kellner
Sabine Tuma-Kellner
WCWalee Chamulitrat
Walee Chamulitrat
FATP4 deficiency in BMDMs and Kupffer cells led to increased proinflammatory response. Fatp4M−/− mice displayed thrombocytopenia, splenomegaly, and elevated liver enzymes. In response to HFHC feeding, male mutants were prone to hepatic steatosis, whereas female mutants showed exaggerated fibrosis. Our study provides insights into a sex-dimorphic susceptibility to NASH by myeloid-FATP4 deficiency.

13 July 2022 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
WCWanatsanan Chulrik
Wanatsanan Chulrik
CJChutima Jansakun
Chutima Jansakun
WCWaraluck Chaichompoo
Waraluck Chaichompoo
ATAman Tedasen
Aman Tedasen
PYPathumwadee Yotmanee
Pathumwadee Yotmanee
WCWarangkana Chunglok
Warangkana Chunglok

7 April 2026 in Foods
Verified
Journal Article
Open access
PDF file
Moragot ChatatikunMoragot Chatatikun
Moragot Chatatikun
ATAman Tedasen
Aman Tedasen
CJChutima Jansakun
Chutima Jansakun
PPPassakorn Poolbua
Passakorn Poolbua
JHJason Huang
Jason Huang
APAtthaphong Phongphithakchai
Atthaphong Phongphithakchai
Alpha-mangostin (AM), a xanthone from Garcinia mangostana, has shown promising nephroprotective properties, but its mechanisms in acute kidney injury (AKI) remain incompletely defined. In this study, we applied an integrative network pharmacology pipeline combined with molecular docking to clarify AM’s multi-target mechanisms in AKI. We identified 128 predicted AM targets and intersected them with AKI-related genes, yielding 122 shared targets. Protein–protein interaction analysis identified ten hub genes—TNF, AKT1, IL6, SRC, CTNNB1, HSP90AA1, NFKB1, HIF1A, PPARG, and PTGS2—implicating inflammatory, hypoxia, and cell-survival pathways. KEGG enrichment highlighted HIF-1 signaling, PI3K–Akt signaling, chemokine signaling, AGE–RAGE signaling, and pathways related to cellular senescence and oxidative stress, while GO terms emphasized responses to chemical/oxygen-containing compounds, kinase activity, signal transduction, and apoptosis. Molecular docking against the ten hub proteins showed favorable binding energies across multiple targets. The strongest predicted affinities were observed for PTGS2 (−11.13 kcal/mol), TNF (−9.74 kcal/mol), and AKT1 (−9.48 kcal/mol). Docking positioned AM within the COX-2 catalytic pocket, engaging key catalytic and hydrophobic residues similar to known inhibitors. MD simulation interaction analysis confirmed that AM maintained stable contacts with key human PTGS2 residues, characterized by dominant hydrogen bonds and water-bridge interactions with SER353, TYR355, ARG513, and SER530, along with consistent hydrophobic contacts, and persistent interactions sustained throughout the 200 ns trajectory. Collectively, these results suggest that AM modulates interconnected inflammatory, hypoxic, and survival pathways relevant to AKI, acting as a multi-target ligand with notable interaction involving COX-2, TNF, and AKT1. Further experimental validation and formulation strategies to improve bioavailability are recommended for the advancement of AM toward therapeutic evaluation in AKI.

13 February 2026 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
WCWanatsanan Chulrik
Wanatsanan Chulrik
RKRungruedee Kimseng
Rungruedee Kimseng
CJChutima Jansakun
Chutima Jansakun
RCRatchanaporn Chokchaisiri
Ratchanaporn Chokchaisiri
ATAman Tedasen
Aman Tedasen
WCWarangkana Chunglok
Warangkana Chunglok

2 May 2023 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
WCWanatsanan Chulrik
Wanatsanan Chulrik
CJChutima Jansakun
Chutima Jansakun
WCWaraluck Chaichompoo
Waraluck Chaichompoo
NSNassareen Supaweera
Nassareen Supaweera
ATAman Tedasen
Aman Tedasen
WCWarangkana Chunglok
Warangkana Chunglok